Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Endometriosis Non-Hormonal Therapy Market: Fertility-Preserving Pain Management Demand, Lesion-Targeted Peptide Therapy Growth, and Prolactin Receptor-Targeting Monoclonal Antibody Adoption to Drive Steady Market Expansion Through 2035

The global Endometriosis Non-Hormonal Therapy Market is projected to expand at a steady CAGR of 18.7% through 2035, driven by sustained demand for fertility-preserving pain management options among patients actively seeking pregnancy, growing clinical development of lesion-targeted peptide therapy, and continued advancement of prolactin receptor-targeting monoclonal antibody technology. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises established NSAID and neuropathic pain therapies alongside an emerging clinical pipeline including HMI-115, a prolactin-receptor-targeting monoclonal antibody, and ENDO-205, a non-hormonal lesion-targeted peptide therapy that received U.S. IND clearance in March 2026.

The market’s steady 18.7% CAGR reflects growing clinical and commercial recognition of non-hormonal endometriosis treatment as a distinct therapeutic category addressing patients for whom hormonal therapy is intolerant, contraindicated, or unsuitable given fertility intentions, generating structured demand from gynecology and fertility treatment centers above discretionary specialty pharmaceutical demand growth. This creates a particularly valuable commercial segmentation given that hormonal therapies are constrained in patients actively seeking pregnancy, establishing a meaningful unmet-need population for non-hormonal disease-modifying and pain-management approaches. Coverage extending across multiple molecular classes, disease manifestations, and fertility status categories underscores the breadth of clinical infrastructure now supporting this increasingly differentiated therapeutic category.

Executive Snapshot

How does fertility-preserving pain management demand drive the endometriosis non-hormonal therapy market?
Gynecology and fertility treatment centers continue to prioritize non-hormonal treatment options for patients actively trying to conceive, given that conventional hormonal endometriosis therapies are generally incompatible with pregnancy intentions, establishing this fertility-preserving positioning as a defining commercial rationale for the category. As awareness of this unmet need continues to grow, procurement associated with fertility-preserving treatment is expected to remain a leading category through the forecast period.

What role does lesion-targeted peptide therapy growth play in market expansion?
Biopharmaceutical developers continue to advance ENDO-205, a non-hormonal lesion-targeted peptide therapy that received U.S. IND clearance in March 2026, sustaining structured demand from developers pursuing this differentiated disease-modifying approach that directly targets endometriotic lesions rather than relying solely on systemic hormonal suppression.

How does prolactin receptor-targeting monoclonal antibody adoption sustain market growth?
Biopharmaceutical developers continue to advance HMI-115, a prolactin-receptor-targeting monoclonal antibody, sustaining structured demand above conventional analgesic and anti-inflammatory approaches. Continued clinical investment in this differentiated biologic mechanism is generating demand from developers pursuing novel non-hormonal disease pathway targeting beyond symptomatic pain management alone.

What is driving demand for non-hormonal therapy in deep infiltrating endometriosis applications?
Developers pursuing non-hormonal candidates for deep infiltrating, bowel, and bladder endometriosis continue to extend treatment beyond superficial peritoneal disease, generating incremental demand among clinical-stage biopharmaceutical developers pursuing this more severe and treatment-resistant disease manifestation category.

How does hormonal-therapy-intolerant patient demand sustain the market?
Gynecology treatment centers increasingly identify patients who are intolerant to, contraindicated for, or have failed hormonal endometriosis therapy, sustaining structured demand from developers pursuing this well-defined patient population requiring non-hormonal treatment alternatives.

Which endometriosis non-hormonal therapy market segments are growing fastest?
The fastest-growing segments include lesion-targeted peptide and monoclonal antibody biologic therapies, fertility-preserving treatment positioning, deep infiltrating and bowel endometriosis indications, and patients with hormonal-therapy intolerance or contraindication.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Endometriosis Non-Hormonal Therapy Market

  • Analgesic and symptomatic therapies sustaining the leading share of current commercial market activity: NSAIDs and related conventional pain management approaches continue to anchor the substantial majority of current non-hormonal endometriosis treatment activity.
  • HMI-115 and ENDO-205 sustaining the leading share of clinical pipeline development activity: These two differentiated biologic and peptide candidates continue to represent the most clinically advanced disease-modifying non-hormonal approaches.
  • Fertility preservation sustaining a distinct and increasingly important commercial positioning strategy: This unmet-need segment continues to differentiate non-hormonal therapy from conventional hormonal treatment approaches incompatible with pregnancy intentions.
  • Chronic pelvic pain and dysmenorrhea sustaining the primary current symptom-management focus: These core endometriosis-associated pain symptoms continue to anchor the therapeutic rationale for both conventional and emerging non-hormonal approaches.
  • Deep infiltrating endometriosis sustaining structured demand growth as a more severe disease manifestation category: This treatment-resistant disease subtype continues to attract developer interest pursuing more targeted disease-modifying therapy.
  • Biologic and peptide therapeutic classes sustaining structured demand growth above conventional small-molecule approaches: Monoclonal antibody and lesion-targeted peptide technology continue to represent an increasingly important area of pipeline innovation beyond established analgesic therapy.

Market Segmentation: Endometriosis Non-Hormonal Therapy Market

By Therapy Type
  • Analgesic / Symptomatic Therapies
  • Neuromodulatory Therapies
  • Anti-inflammatory Therapies
  • Disease-Modifying Therapies
  • Biologic Therapies
  • Targeted Small-Molecule Therapies
  • Microbiome / Cellular Therapies
  • Novel / Next-Generation Therapies
By Product
  • NSAIDs
  • COX-2 inhibitors
  • Neuropathic-pain drugs
  • HMI-115
  • ENDO-205
  • Anti-inflammatory pipeline candidates
  • Anti-angiogenic candidates
  • Anti-fibrotic candidates
  • Lesion-targeted peptide therapies
  • Others
By Molecular Class
  • Small molecules
  • Monoclonal antibodies
  • Peptides
  • Recombinant proteins
  • RNA therapeutics
  • Gene therapies
  • Cell-based therapies
  • Microbiome-based therapeutics
  • Other biologics
By Target
  • Prolactin / prolactin receptor
  • Inflammatory cytokines
  • NF-κB pathway
  • COX / prostaglandin pathway
  • Angiogenesis pathways
  • VEGF signaling
  • Fibrosis pathways
  • Immune-cell signaling
  • Pain / sensory-neuron pathways
  • Neuroinflammation
  • Oxidative stress
  • Lesion survival pathways
  • Apoptosis / autophagy
  • Cell adhesion / invasion
  • Other disease-specific targets
By Mechanism of Action
  • Pain inhibition
  • Prostaglandin inhibition
  • Neuroinflammation reduction
  • Cytokine suppression
  • Immune modulation
  • Angiogenesis inhibition
  • Fibrosis inhibition
  • Lesion growth inhibition
  • Lesion elimination
  • Abnormal cell proliferation inhibition
  • Apoptosis induction
  • Tissue remodeling
  • Neural sensitization reduction
  • Peripheral nociceptor modulation
By Disease Stage
  • Mild
  • Moderate
  • Moderate-to-severe
  • Severe
  • Refractory
  • Chronic / recurrent
  • Deep infiltrating / severe disease
By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Intranasal
  • Topical
  • Vaginal
  • Local / lesion-directed
  • Other routes
By Patient Type
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
By Formulation
  • Tablets
  • Capsules
  • Oral solutions
  • Injectable
  • Long-acting injectable
  • Nasal formulation
  • Topical formulation
  • Targeted peptide formulation
  • Other formulations
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Gynecology clinics
  • Endometriosis specialty centers
  • Hospitals
  • Women’s health clinics
  • Pain-management centers
  • Fertility / reproductive medicine centers
  • Academic medical centers
  • Specialty pharmacies
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Endometriosis Non-Hormonal Therapy Market

  1. Sustained recognition of the fertility-preservation unmet need driving continued non-hormonal treatment demand: Patients actively seeking pregnancy continue to represent a structurally important market segment given hormonal therapy’s general incompatibility with fertility intentions.
  2. Growing clinical development of disease-modifying peptide and biologic therapy supporting pipeline diversification: ENDO-205 and HMI-115 continue to attract structured developer investment pursuing differentiated mechanisms beyond conventional analgesic approaches.
  3. Continued biopharmaceutical investment in prolactin receptor and other novel pathway targeting supporting mechanism diversification: These differentiated biologic approaches continue to attract structured research investment relative to established small-molecule pain management therapy.
  4. Sustained clinical focus on deep infiltrating and bowel endometriosis broadening the addressable severity-based market: These treatment-resistant disease manifestations continue to generate incremental developer interest in more targeted disease-modifying therapy.
  5. Growing identification of hormonal-therapy-intolerant patients supporting well-defined non-hormonal treatment eligibility: This patient population continues to represent a clear and actionable segment for non-hormonal treatment development.
  6. Maturing clinical pipeline supporting continued diversification of the non-hormonal treatment landscape: Recent IND clearance and continued Phase I and Phase II development across multiple candidates continues to focus treatment center and payer attention on the category’s ongoing evolution.

Regional Outlook: Endometriosis Non-Hormonal Therapy Market

  • North America: The United States accounts for the largest share of regional demand, supported by extensive gynecology and fertility treatment center infrastructure and leading clinical trial activity in non-hormonal endometriosis therapy development; regional treatment centers continue to expand specialized capacity to accommodate this demand.
  • Europe: Germany, the United Kingdom, and France anchor regional demand, supported by growing specialized endometriosis center capacity and consistent clinical trial activity; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as treatment access expands and regional biopharmaceutical developers advance their own non-hormonal endometriosis therapy pipelines; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized gynecology and fertility centers begin to participate in non-hormonal endometriosis therapy clinical trials; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Endometriosis Non-Hormonal Therapy Market

Key Players
Hutchmed Limited, Enteris BioPharma, Inc., Bayer AG, AbbVie Inc., Myovant Sciences (Sumitomo Pharma America, Inc.), Organon & Co.

  • Hutchmed Limited [March 2026] — confirmed continued clinical development of HMI-115, its prolactin-receptor-targeting monoclonal antibody for endometriosis, with the company noting sustained investigator interest in this novel non-hormonal mechanism.
  • Enteris BioPharma, Inc. [December 2025] — reported the U.S. IND clearance of ENDO-205 in March 2026, its non-hormonal lesion-targeted peptide therapy for endometriosis, with the company noting planned initiation of clinical development.
  • AbbVie Inc. [September 2025] — confirmed continued research investment in non-hormonal endometriosis treatment approaches, with the company reporting structured interest in complementing its existing hormonal therapy portfolio with disease-modifying alternatives.

Consultant POV

The Endometriosis Non-Hormonal Therapy Market’s steady 18.7% CAGR outlook through 2035 is anchored in sustained fertility-preserving pain management demand, growing lesion-targeted peptide therapy activity, and continued prolactin receptor-targeting monoclonal antibody adoption. Sustained clinical investment from companies including Hutchmed Limited, Enteris BioPharma, Inc., and AbbVie Inc. confirms the Endometriosis Non-Hormonal Therapy Market will sustain steady growth through 2035.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report